Who are Dapagliflozin + Lobeglitazone's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dapagliflozin-lobeglitazone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Dapagliflozin + Lobeglitazone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dapagliflozin + Lobeglitazone (Dapagliflozin + Lobeglitazone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SGLT2 inhibitor + thiazolidinedione combination. Area: Diabetes.

marketed SGLT2 inhibitor + thiazolidinedione combination SGLT2 and PPAR-γ Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Dapagliflozin + Lobeglitazone (Dapagliflozin + Lobeglitazone) — Seoul National University Bundang Hospital. This combination reduces blood glucose by inhibiting sodium-glucose cotransporter 2 (SGLT2) in the kidneys while simultaneously activating peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dapagliflozin + Lobeglitazone TARGET	Dapagliflozin + Lobeglitazone	Seoul National University Bundang Hospital	marketed	SGLT2 inhibitor + thiazolidinedione combination	SGLT2 and PPAR-γ

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SGLT2 inhibitor + thiazolidinedione combination class)

Seoul National University Bundang Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dapagliflozin + Lobeglitazone — Competitive Intelligence Brief. https://druglandscape.com/ci/dapagliflozin-lobeglitazone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab